New Impact Factors for BPS journals

01 August 2014

The British Pharmacological Society (BPS) is pleased to announce the new Impact Factor results for its journals:

  • British Journal of Clinical Pharmacology achieved another strong result of 3.688, its highest ever Impact Factor (2012: 3.578)
  • British Journal of Pharmacology maintained its 21/254 ranking amongst Pharmacology and Pharmacy journals with an Impact Factor of 4.990 (2012: 5.067)

Professor Graeme Henderson, BPS Vice President – Publications, comments: “BPS journals continue to support the Society’s aim to promote and advance pharmacology, including clinical pharmacology. These strong Impact Factor results are an opportunity to congratulate our editors, publishers and those who referee submissions to our journals, and thank them all for their enthusiasm and commitment.”

BPS advocates the importance of evidence-based scientific advice in Europe

28 July 2014

On 22 July, nine representatives from environmental NGOs wrote to the President elect of the European Commission, Jean-Claude Juncker, asking him to 'scrap the position' of Chief Scientific Advisor. BPS has joined ten other organizations by signing a Sense about Science coordinated letter to Mr Juncker in support of the position and of independent scientific evidence in policy making.

Putting UK Pharmacology on the Map: get involved

09 July 2014

The British Pharmacological Society's initiative Putting UK Pharmacology on the Map, led by the External Affairs Committee, is designed to increase awareness of the Society and pharmacology by announcing sites of special pharmacological interest in the UK – providing an opportunity to engage external audiences nationally as well as locally to each site. Highlights and winners from 2013.

Congratulations to BPS Honorary Fellow Professor Colin Blakemore

16 June 2014

Congratulations to BPS Honorary Fellow, Professor Colin Blakemore FRS, on his knighthood for services to Scientific Research, Policy and Outreach.

Congratulations to winners of BPS prizes and awards

04 June 2014

The British Pharmacological Society is proud to announce the names of the winners of its recently-judged prizes and awards – worth up to £14,750 in total. These will be officially awarded as part of the Society’s flagship meeting Pharmacology 2014, at the Annual Dinner and Prize-Giving.

BPS begin voting for the Pharmacology Hall of Fame

04 June 2014

British Pharmacological Society members will today start voting to elect new trailblazers in drug discovery and development to the Society’s Pharmacology Hall of Fame. This posthumous honour celebrates individuals, based upon their distinction and peer recognition in science and/or long and valuable service to the Society.

Drug Discovery of the Year 2015 opens for nominations

21 May 2014

The British Pharmacological Society is now accepting nominations for its third Drug Discovery of the Year award. The award was established by the Society in 2012 to demonstrate the importance of pharmacology in the development of new medicines, and to reward the achievements of the teams of scientists who discover and develop these drugs.

BPS signs Concordat on openness on animal research in the UK

14 May 2014

BPS has signed Concordat on openness on animal research in the UK and joins the 72 universities, charities, commercial companies, research councils, umbrella bodies and other learned societies committing to help the public understand more about animal research.

What has takeover target AstraZeneca done for the UK?

13 May 2014

On the day that the heads of Pfizer and AstraZeneca appear in front of MPs, BPS President Emeritus Professor Ray Hill argues that the UK economy, science base and skills have all benefited from AstraZeneca's work.

Read the article on Channel 4 news website.

Joint statement on the UK pharmaceutical industry

01 May 2014

BPS and three other learned societies have issued a joint statement regarding the UK pharmaceutical industry:

Whatever the outcome of Pfizer's declared interest in taking over AstraZeneca, it is another sign of the global trend for pharmaceuticals. The UK has been a world-leader in medicines research and development, but recent closures and restructuring put this position under threat. Drug discovery is changing everywhere: large pharma businesses are consolidating and downsizing, with much of early-stage research coming from an innovation ecosystem of academia and SMEs.

The UK can stay at the cutting edge and reap the economic rewards if we act now, while the sector remains strong, to support the transition to the new drug discovery model. When the automotive industry faced similar challenges, a Government-sponsored Automotive Council played a key role in re-invigorating the sector – and now a new vehicle rolls off a UK production line every 20 seconds. The Government must again lead the way, by establishing a Pharmaceutical Council to bring together medical charities, funding bodies, businesses, academics, the NHS and learned societies to ensure the UK is the best place in the world to do drug discovery.

Dr Robert Parker, chief executive, Royal Society of Chemistry
Mr Jonathan Bruun, chief executive, British Pharmacological Society
Dr Mark Downs, chief executive, Society of Biology
Ms Kate Baillie, chief executive, Biochemical Society

Page:   1 2 3 4 5 6 Next
Search the News

Search Area

Search the Site
Advanced Search

Members' Login Area

Members' Login U: P:

Need Help?